Patents by Inventor Andrew David Goodearl

Andrew David Goodearl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glial mitogenic factors, their preparation and use
    Patent number: 7968678
    Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
    Type: Grant
    Filed: December 27, 2007
    Date of Patent: June 28, 2011
    Assignees: Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
    Inventors: Andrew David Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchionni, Maio Su Chen, Ian Hiles
  • Glial mitogenic factors, their preparation and use
    Publication number: 20090246867
    Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
    Type: Application
    Filed: December 27, 2007
    Publication date: October 1, 2009
    Inventors: Andrew David Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchionni, Maio Su Chen, Ian Hiles
  • Glial mitogenic factors lacking an N-terminal signal sequence
    Patent number: 7319019
    Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Also included is the mature GGF peptide and the DNA encoding said peptide, exclusive of the N-terminal signal sequence. The mature GGF peptide and DNA encoding the same are also useful for treatment of conditions of the central nervous system. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
    Type: Grant
    Filed: October 22, 1996
    Date of Patent: January 15, 2008
    Assignees: Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
    Inventors: Andrew David Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchionni, Maio Su Chen, Ian Hiles
  • Method for treating nervous system pathophysiologies using glial growth factors
    Patent number: 6204241
    Abstract: Disclosed are methods for treating pathophysiological conditions of the mammalian nervous system. The methods involve administering an effective amount of a polypeptide comprising amino acids 51 to 422 of human GGF2.
    Type: Grant
    Filed: October 22, 1996
    Date of Patent: March 20, 2001
    Assignees: Cambridge NeuroScience, Inc., Ludwig Institute for Cancer Research
    Inventors: Andrew David Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchionni, Maio Su Chen, Ian Hiles
  • Glial growth factors
    Patent number: 5716930
    Abstract: The invention involves secretable glial growth factors.
    Type: Grant
    Filed: May 26, 1994
    Date of Patent: February 10, 1998
    Assignees: Ludwig Institute for Cancer Research, Cambridge Neuroscience
    Inventors: Andrew David Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchionni, Maio Su Chen, Ian Hiles